Kornimate/medical-research-clean huggingface dataset:
exercise training in treating diastolic heart failure

Conditions: Heart Failure, Diastolic; Ventricular Dysfunction, Left

Summary: the purpose of this study is to determine whether endurance exercise of either high or moderate intensity can reverse structural and functional changes of the heart in patients with diastolic heart failure, and to investigate which type of exercise is best in terms of aerobe capacity and quality of life. the investigators expect that high intensity endurance exercise is superior to moderate intensity endurance exercise.

this study is a prospective randomized controlled intervention study comparing two active arms. eligible patients are being sampled consecutively by cardiologists, and randomized to either high or moderate intensity endurance exercise. endpoints are measured at baseline, 4 weeks and 7 months. the intervention is considered safe, and the study has been approved by the regional ethics committee (rek-midt). this project has been financially supported by the norwegian extrafoundation for health and rehabilitation through extra funds.

Eligibility criteria:
inclusion criteria: * sedentary lifestyle * normal systolic function left ventricular ejection fraction (lvef) \< 50% * new york heart association (nyha) class ii or iii * diastolic dysfunction (e/é \ 220pg/ml) * medically stable the last 4 weeks * written informed consent exclusion criteria: * other causes of dyspnea than diastolic heart failure * personal preferences or characteristics prohibiting the person from attending inpatient cardiac rehabilitation * not able to perform physical exercise

Keywords: exercise therapy
multimodal analysis of the young brain on rhythm perception: from premature neonates to infants

Conditions: Time Perception; Rhythm; EEG; fNIRS; ERP; Premature Neonates; Discrimination

Summary: premature neonates are able to discriminate phonemes and voice from 28wga at a time the neuronal network establish contact between the environment and the cortical neurones. in the present monocentric study the investigators will analyse the response of the cortical network in premature aged between 28 and 40 wga in response to auditory stimuli using high resolution electroencephalography and high density near infrared spectroscopy


Eligibility criteria:
inclusion criteria: * full term neonates between 28 and 40 weeks gestational age exclusion criteria: * neonates outside the age range

Keywords: time perception rhythm eeg fnirs erp premature neonates discrimination
study of ucart19 in pediatric patients with relapsed/refractory b acute lymphoblastic leukemia

Conditions: Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed B-cell Acute Lymphoblastic Leukemia

Summary: this study aims to evaluate the safety and feasibility of ucart19 to induce molecular remission in pediatric patients with relapsed or refractory cd19-positive b-cell acute lymphoblastic leukemia (b-all).


Eligibility criteria:
inclusion criteria: * patient with relapsed or refractory cd19-positive b-acute lymphoblastic leukaemia (b-all) who have exhausted alternative treatment options. * estimated life expectancy ≥ 12 weeks * lansky (age \< 16 years at the time of assent/consent) or karnofsky (age ≥ 16 years at time of assent/consent) performance status ≥ 50 exclusion criteria: * burkitt leukemia * cd19-negative b-cell leukemia * active central nervous system (cns) leukemia * active acute or chronic graft-versus-host disease (gvhd) requiring systemic use therapy within 4 weeks before ucart19 infusion * patients with autoimmune disease requiring systemic immunosuppression therapy that cannot be stopped * history of crs grade 4 related to previous car t cell therapy * contraindication to alemtuzumab administration
newcastle disease virus (ndv) for cancer patients resistant to conventional anti-cancer modalities

Conditions: Metastatic Cancer; Newcastle Disease Virus (NDV)

Summary: ndv is a virus tht is harmful in chicken, but harmless in man. there are 2 major sub-strains of ndv, one oncolytic and one non-oncolytic. oncolytic ndv (mth-68h) preferentially homes and replicates in cancer cells and therefore, administration of ndv intravenously or preferentially intra-tumor, either by direct injection or by injection into an afferent artery results in direct lysis of tumor cells. ndv activates apoptotic mechanism in cancer cells and thus, results in natural cell death. both oncolytic and non-oncolytic ndv were used clinically in hundreds of patients with different types of cancer worldwide. ndv were proved harmless in man. clinical studies were done for more than a decade and the efficacy of ndv was documented on pre-clinical animals models as well as in man. for a large number of patients with metastatic cancer and chemotherapy resistant hematological malignances, no cure can be provided by conventional anti-cancer modalities, new treatment options are urgently indicated. the goal of the study is to use ndv, in order to provide such treatment for patients in need.


Eligibility criteria:
inclusion criteria: * patients with the following disease category will be eligible: patients with metastatic lung cancer, metastatic gi cancer, metastatic urogenital cancer, skin and soft tissue cancer. * failure to anti-cancer modalties and evidence of progressive disease despite optimal application of all relevant available anti-cancer modalities. * consenting patients. * the patient should sign a consent form stating that he/she will make sure to avoid any contact with chicken or any other species of birds. exclusion criteria: * not fulfilling any of the above criteria. * moribund patients or patients with life-expectancy \<3 months. * karnofsky performance status \<60%. * pregnant or lactating women. * active local or systemic infections requiring treatment. * co-morbidity or life-threatening clinical condtion other than the basic cancer.

Keywords: immunotherapy
study hza106829: efficacy/safety study of fluticasone furoate/vilanterol (gw642444) in adult and adolescent asthmatics

Conditions: Asthma

Summary: the purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (gw642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.


Eligibility criteria:
inclusion criteria: * outpatient at least 12 years of age * both genders; females of childbearing potential must be willing to use birth control method * pre-bronchodilator fev1 of 40-90% predicted * reversibility fev1 of at least 12% and 200mls * current asthma therapy that includes an inhaled corticosteroid for at least 12 weeks prior to first visit exclusion criteria: * history of life-threatening asthma * respiratory infection or oral candidiasis * asthma exacerbation within 12 weeks * concurrent respiratory disease or other disease that would confound study participation or affect subject safety * allergies to study drugs, study drugs' excipients, medications related to study drugs * taking another investigational medication or medication prohibited for use during this study

Keywords: fluticasone propionate asthma vilanterol gw642444 fluticasone furoate
cognitive impairments in children with epilepsy

Conditions: Epilepsy Syndrome

Summary: since the proportion of language and attentional difficulties in patients with epilepsy is recognized, both in the literature and in the clinical experience of practitioners, it is appropriate to propose a complete speech-language assessment of oral language and attention.this study investigates these impairments through the taking of specific tests. the general objective of this study is to observe possible oral language and attention disorders in children with epilepsy, by age and etiology of epilepsy. the objective of this work is to study therapeutic apheresis (including plasma exchange and immunoadsorption) among french neuropediatric tertiary centers and to prove that this treatment modality is effective and well tolerated in pediatric neurology diseases.


Eligibility criteria:
inclusion criteria: the subjects should : * be at least 3 years old and at most 15 years old * be french speaker * be in a regular class * have a diagnosis of epilepsy exclusion criteria: * subjects schooled in iem * subjects diagnosed with austim spectrum disorder * subjects with a motor or visual handicap * subjects with psychiatric disorders

Keywords: speech therapy neurology children oral language attention type of epilepsy (focal epilepsy or generalized epilepsy) etiology of epilepsy (unknown, idiopathic, structural, metabolic, immune, infectious) epilepsy syndrome
the effect of acupressure application on menopausal symptoms

Conditions: Menopausal Syndrome

Summary: the study was conducted randomly controlled to determine the effect of acupressure application on menopausal complaints among women who applied to cancer early diagnosis and screening center.

research, between september 2019 and february 2020 of cancer in the body healthy life center in the east of the provincial center of turkey was held by early diagnosis and screening center that refer to women. the universe and sample of the research the universe of the study consisted of women who applied to cancer early diagnosis and screening center for examination for any reason. the calculation of the sample size of the study was determined according to the studies in which non-pharmacological methods were used to cope with menopausal symptoms. the calculation was determined according to the effect size of 0.5 in a moderate level, considering the effect size ranging between (0.25-0.83) reported by the studies on the subject.

Eligibility criteria:
inclusion criteria: * in the 45-65 age range. exclusion criteria: * receiving pharmacological treatment related to menopause, * having a communication problem, * have a hearing problem * it is the presence of tissue deformity in its extremities.
follow up glucose levels among infants of diabetic mothers

Conditions: Newborn; Full Term; Diabetic Mother

Summary: infants to diabetic mothers (idm) are at risk for developing hypoglycemia after birth. glucose level follow ups are recommended to each idm. however, there are no recommendations as to how long this follow up should be performed for, nor are there "safe" glucose levels that allow stopping glucose monitoring. the aim of the study is to retrospectively follow up glucose levels among idms in order to find risk factors for developing hypoglycemia and determine time and glucose levels that would permit monitoring cessation.

a retrospective study of 250-300 idms, born in a single large medical center. data will be collected as follows: gestational age, birth weight, sex, delivery mode, type of maternal diabetes, other maternal diseases, feeding mode. glucose levels as were recorded according to newborn protocol (1,2,4,6 hours after delivery, and then every 8 hours for total of 48 hours). data of hypoglycemia treatment, if given, will be collected. later we will statistically try to determine the risk factors for developing hypoglycemia and the "safe" time and glucose levels to stop monitoring.

Eligibility criteria:
inclusion criteria: * full-term infants, diabetic mothers, singleton exclusion criteria: * preterm infants, multiple pregnancy, congenital malformations, clinically ill at birth.

Keywords: gestational diabetes newborn hypoglycemia
effect of diacerein on hand osteoarthritis

Conditions: Osteoarthritis

Summary: ostearthritis is one of the most common arthritis, affecting more than 30% of aged people world-widely. the disease is characterized by pain and stiffness of the affected joints and is the most common cause of disability in aged people. it commonly affects knee, hip, hand and spine joints. diacerein is a drug developed specifically for the treatment of osteoarthritis. it has inhibitory effects on interleukin-1 (il-1) and metalloproteases which are known to play key roles in the pathogenesis of osteoarthritis while exerting no effect on phospholipase a2, cyclooxygenase or lipoxygenase. it showed anti-inflammatory effects on animal models and reduced structural changes in several animal models. therefore, we investigate the role of diacerein in patients with hand osteoarthritis.


Eligibility criteria:
inclusion criteria: * ages over 40 years-old * conforming to the classification criteria of american college of rheumatology\* * more than 1 tender joints * self reported hand pain which is more than 30 mm on the australian/canadian osteoarthritis hand index visual analogue scales (vas) after wash out period of 2 weeks exclusion criteria: * pregnant or lactating women * previous history of hypersensitivity to diacerein * patients who had taken oral corticosteroid or intraarticular steroid to hand joints within 3 months of enrollment * patients who were injected with hyaluronic acid to hand joints within 6 months of enrollment * patients who underwent surgery in any joints of the hands * ast/alt \> 2x upper normal range * serum cr \> 1.4 mg/dl * patients who have severe comorbidities such as severe congestive heart failure or pulmonary disease * patients who took oral anticoagulants. * patients who refuse to sign the consent form

Keywords: diacerein osteoarthritis hand
adequacy of perioperative cefazolin for surgery antibiotic prophylaxis in obese patients

Conditions: Obesity

Summary: the population continues to increase in weight. currently there are no guidelines in the dosing of cefazolin for the obese population. standard dosing of cefazolin 2 grams for patients \ 120 kg is used as the dose for surgical prophylaxis. this makes no provisions for weight based dosing. there has been some recent data which states this might not be enough for the obese patients. the primary objective of this study is to determine if weight based dosing (30 mg/kg) of cefazolin as surgical prophylaxis for patients undergoing elective gastric bypass/laparoscopic roux-en-y gastric bypass provides appropriate serum concentrations for a larger percentage of time than the current method of giving the standard 2 or 3 gram doses of cefazolin peri-operatively. the concentration of cefazolin in tissue will also be measured to help assess this question.

the hypothesis of this study is that customary doses of antibiotics, when administered for perioperative surgical prophylaxis, are insufficient to achieve adequate antibiotic concentrations in blood and tissues of morbidly obese patients (defined as a bmi greater than 40 kg/m2) and that these patients are therefore placed at high risk of surgical wound infections and poor clinical outcomes. cefazolin is a first-generation cephalosporin commonly used for perioperative surgical prophylaxis in colorectal, abdominal, bariatric, gynecologic and obstetric, or orthopedic total joint arthroplasty surgical procedures. previous cefazolin pharmacokinetic (pk) analysis in obese patients led to conflicting results and recommendations. it is not clearly know to what extent the pharmacokinetics of cefazolin in morbidly obese patients differ from those of non-obese patients. specific dosing guidelines are then lacking. the main objective of this study is to assess the pharmacokinetics of cefazolin in morbidly obese after administrations of a standard recommended 2-3 g dose or a weight-base 30-mg/kg dose

Eligibility criteria:
inclusion criteria: 1. bmi greater than 40 2. no known history of allergy to cephalosporins 3. scheduled for elective gastric bypass or laparoscopic roux-en-y gastric bypass procedures 4. able to read and understand english exclusion criteria: 1. patients \ 89 years of age 2. pregnant women, prisoners and decisionally challenged subjects will be excluded

Keywords: perioperative antibiotic prophylaxis morbidly obese
rapid detection of covid-19 by portable and connected biosensor

Conditions: Sars-CoV2

Summary: the objective of study is to estimate the sensitivity and specificity of the cor-dial based on nasopharyngeal samples taken at the patient's admission in relation to the final diagnosis of covid-19 made by the medical team.


Eligibility criteria:
inclusion criteria: * male or female or child without age limit * admitted to a reference health establishment in an emergency unit, hospitalisation or intensive care unit for suspicion of sars-cov-2 infection, regardless of the clinical presentation and degree of severity. * patient to be diagnosed using a pcr test on nasopharyngeal swab. * social insured exclusion criteria: * atypical or suspicious cases without a final diagnosis of covid-19 positive or negative * patient refusal to participate
a study of the efficacy and safety of lisocabtagene maraleucel (liso-cel) as first-line therapy in adults with transplant-ineligible primary central nervous system lymphoma

Conditions: Lymphoma

Summary: the purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (breyanzi/liso-cel/bms-986387) in adults as first-line treatment in transplant-ineligible primary central nervous system lymphoma (pcnsl).


Eligibility criteria:
inclusion criteria: * participant must be 18 years or older at the time of signing the informed consent form (icf). * histologically confirmed primary central nervous system (cns) lymphoma (pcnsl) prior to screening, as assessed by local pathology. * transplant-ineligible based on physician's assessment and meeting at least one of the following criteria: age ≥65 years or hct-ci (hematopoietic cell transplantation-specific comorbidity index) score ≥3. * participant must be suitable, per investigator, to receive a high dose methotrexate (hd-mtx) based treatment regimen. * prior to signing icf, anti-cancer therapy for the treatment of pcnsl must only include standard of care regimens, with or without corticosteroids given for disease-related symptoms. * prior to icf signature, participant's disease must be sensitive to prior high-dose methotrexate-based regimens, as demonstrated by a complete response (cr, no remaining signs of pcnsl) or a partial response (pr, signs of pncsl mostly gone) per investigator's assessment, based on the international primary cns lymphoma collaborative group (ipcg) criteria. * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. * individuals of childbearing potential (iocbp) must have a negative highly sensitive pregnancy test within 24 hours prior to the start of study intervention. exclusion criteria: * participant has a diagnosis of secondary cns lymphoma due to systemic disease. * primary intraocular lymphoma (piol)/ primary vitreoretinal lymphoma (pvrl) and isolated cerebrospinal fluid (csf) disease. * any significant medical condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she was to participate in the study based on investigator's judgement. * history of another primary malignancy that has not been in remission for ≥2 years. * prior treatment with car t-cell or any other gene therapy product that utilizes human genome-editing technology. * history of or active human immunodeficiency virus (hiv). * active hepatitis b or active hepatitis c. * active autoimmune disease requiring immunosuppressive therapy. * other protocol-defined inclusion/exclusion criteria apply.
hormone suppression and radiation therapy for 6 months with/without docetaxel for high risk prostate cancer

Conditions: Prostate Cancer

Summary: this randomized study is looking at the benefits of using docetaxel (chemotherapy) added to one of the standard treatments (radiation and hormones) for men with high-risk prostate cancer.

radiation therapy plus six months of hormone therapy is one standard way of treating men with high-risk prostate cancer. in this study, we want to see whether or not adding the chemotherapy drug docetaxel (taxotere)will make this treatment more effective. docetaxel has shown a benefit in median survival when given to men who have become resistant to hormonal therapy and in men who have metastatic prostate cancer (spread to other areas of the body).

Eligibility criteria:
inclusion criteria: * biopsy proven prostate cancer * clinical tumor category t1b, t1c, t2a and psa greater than (\>) 10 or gleason score equal or greater than 4+3=7 or psa velocity \> 2.0 ng/ml per year and also eligible patients with tumor category t2c, t3a, t3b, or t4 as per 2002 ajcc guidelines. any minor tertiary grade of gleason 5; biopsy proven or radiographic (ermri seminal vesicle invasion); gleason = or \> 3+4=7 with 50% or more cores positive * negative bone scan * lymph node assessment by ct or mr * adequate hematologic function (blood counts) * adequate liver functions (blood tests) * ecog performance status 0 or 1 * peripheral neuropathy must be =\< grade 1 * psa obtained within 3 months of entry exclusion criteria: * prior history of malignancy that are \< 5 years except for cancers found to be "in-situ" and would not likely impact a patient's life expectancy with appropriate medical management. * prior pelvic radiation therapy * prior hormonal therapy (up to 4 weeks prior to enrollment allowed) * individuals unable to tolerate lying still 5 - 10 minutes * patients with a history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate 90.

Keywords: prostate cancer hormone refractory metastatic localized locally advanced prostate cancer - high risk localized or locally advanced
tick-borne encephalitis and positive borrelial antibodies

Conditions: Tick-borne Encephalitis

Summary: in slovenia, tick-borne encephalitis and lyme borreliosis are both endemic diseases with high incidence rates and they are both transmitted by a bite of infected ixodes ricinus tick. in clinical practice, tick-borne encephalitis is confirmed by demonstration of tick-borne encephalitis antibodies in serum of a patient with compatible clinical presentation and cerebrospinal pleocytosis. patients with lyme meningitis or meningoradiculitis also have cerebrospinal pleocytosis, however the presence of borrelial antibodies in serum does not attest lyme neuroborreliosis. patients with tick-borne encephalitis and positive borrelial antibodies in serum, but not fulfilling criteria for lyme neuroborreliosis, are often being treated with antibiotics in several european countries due to the possibility of double infection. the investigators hypothesise that such patients do not benefit from antibiotics. such an approach may appear safe regarding the possibility of borrelial infection, however it can also be associated with detrimental consequences such as antibiotic related adverse reactions, negative epidemiological impact on bacterial resistance, and intravenous catheter related complications.


Eligibility criteria:
inclusion criteria: * 18 years or older * clinical picture compatible with tick-borne encephalitis, * clear cerebrospinal fluid, * cerebrospinal pleocytosis (leucocytes in cerebrospinal fluid \>5 x 106/)l, * positive serum immunoglobulin m (igm) and immunoglobulin g (igg) antibodies against tick-borne encephalitis virus, * positive serum igg antibodies against lyme borreliae. exclusion criteria: * isolation of b.burgdorferi sensu lato from cerebrospinal fluid, * positive intrathecal borrelial antibody production index, * seroconversion of borrelial igg antibodies, * presence of erythema migrans and/or borrelial lymphocytoma in the last month, * bannwarth syndrome.